Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Neurology Diabetes / Metabolic Rheumatology Gastroenterology Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial Active — Not Recruiting Non-phase study NCT05949645

Study to Assess Safety, Feasibility, and Preliminary Efficacy of the Apreo Implant for Severe Emphysema

Study to Assess Safety, Feasibility, and Preliminary Efficacy of the Apreo Implant for Severe Emphysema — Active Not Recruiting • Non-phase study • Respiratory / COPD / Asthma…

📅 31 Mar 2026 ⏱ 1 min read
Active — Not Recruiting
Check the registry for current status and eligibility criteria.
Status
Active — Not Recruiting
Phase
Non-phase study
NCT ID
NCT05949645
Start
2023-08-15
Completion
2024-10-08
ClinicaliQ Trial Snapshot
  • Study to Assess Safety, Feasibility, and Preliminary Efficacy of the Apreo Implant for Severe Emphysema — Active Not Recruiting • Non-phase study • Respiratory / COPD / Asthma • NCT05949645.
  • Review the linked registry entry for study design, population, endpoints, and operational status.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The goal of this clinical trial is to test the feasibility of an implant for severe emphysema in up to 30 participants at up to 5 study centers located in Europe and the United Kingdom. The main questions this clinical trial aim to answer are: Is it safe? Does it work? Participants who meet eligibility criteria will have up to two procedures 30 days apart, in which up to 3 implants will be placed in each lung during the procedure(s). Participants will be asked to return for follow-up visits at…

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Digital technologies for applying algorithms to spirometry to support asthma and COPD diagnosis in primary care and community diagnostic centres: early-use assessment
Respiratory / COPD / Asthma · 02 Apr 2026
Digital spirometry algorithms can improve diagnostic accuracy for asthma and COPD in primary care and community diagnostic centres, potentially reducing unnecessary referrals…
View guideline →
Guideline
GINA 2024 Report: Global Strategy for Asthma Management and Prevention
Respiratory / COPD / Asthma · 31 Mar 2026
GINA 2024 reinforces no SABA-only treatment for any asthma severity: all patients should receive ICS-containing controller therapy or ICS-formoterol MART as first-line…
View guideline →
Clinical Brief
Short-acting beta 2 agonists (SABA) (salbutamol and terbutaline): reminder of the risks from overuse in asthma and to be aware of changes in the SABA prescribing guidelines
Respiratory / COPD / Asthma · MHRA · 24 Apr 2025
Healthcare professionals and patients are reminded of the risk of severe asthma attacks and increased mortality associated with overuse of SABA with…
View brief →
Guideline
2021 ESCMID Guidelines for the Management of Community-acquired Pneumonia
Respiratory / COPD / Asthma · 30 Mar 2026
This ESCMID guideline addresses 2021 ESCMID Guidelines for the Management of Community-acquired Pneumonia in Respiratory / COPD / Asthma. Use it to…
View guideline →
Guideline
Mepolizumab for Treating Severe Refractory Eosinophilic Asthma (NICE TA431)
Respiratory / COPD / Asthma · 27 Mar 2026
Initiate mepolizumab 100 mg subcutaneously once monthly only in adults with severe eosinophilic asthma inadequately controlled on high-dose inhaled corticosteroids plus long-acting…
View guideline →
Clinical Brief
Asthma and COPD patients to receive better care closer to home
Respiratory / COPD / Asthma · NHS England · 17 Mar 2026
Asthma and chronic obstructive pulmonary disease (COPD) patients will receive better care closer to home under a landmark £10 million partnership. This…
View brief →